PEG-ing down (and preventing?) the cause of pegloticase failure

Arthritis Research and Therapy

Volumn 16, Issue 3, 2014, Pages

  Abeles, Aryeh M ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; MACROGOL; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTRALIZING ANTIBODY; PEGLOTICASE; URIC ACID; GOUT SUPPRESSANTS; POLYETHYLENE GLYCOLS; URATE OXIDASE;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; DRUG EFFICACY; DRUG TREATMENT FAILURE; EDITORIAL; GOUT; HUMAN; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; MEDICATION COMPLIANCE; URIC ACID BLOOD LEVEL; FEMALE; HUMANS; IMMUNOLOGY; MALE;

FEMALE; GOUT; GOUT SUPPRESSANTS; HUMANS; MALE; POLYETHYLENE GLYCOLS; URATE OXIDASE;

EID: 84901654683     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4572     Document Type: Editorial

References (7)

1. Hershfield MS, Ganson NJ, Kelly SJ, Scarlett EL, Jaggers DA, Sundy JS. Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients. Arthritis Res Ther 2014, 16:R63. 10.1186/ar4500, 24602182.
2. Schellekens H, Hennink WE, Brinks V. The immunogenicity of polyethylene glycol: facts and fiction. Pharm Res 2013, 30:1729-1734. 10.1007/s11095-013-1067-7, 23673554.
3. Lipsky PE, Calabrese LH, Kavanaugh A, Sundy JS, Wright D, Wolfson M, Becker MA. Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis Res Ther 2014, 16:R60. 10.1186/ar4497, 24588936.
4. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998, 41:1552-1563. 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W, 9751087.
5. Krieckaert CL, Nurmohamed MT, Wolbink GJ. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis 2012, 71:1914-1915. 10.1136/annrheumdis-2012-201544, 22586169.
6. Kapetanovic MC, Saxne T, Sjöholm A, Truedsson L, Jönsson G, Geborek P. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford) 2006, 45:106-111.
7. Keenan RT, O'Brien WR, Lee KH, Crittenden DB, Fisher MC, Goldfarb DS, Krasnokutsky S, Oh C, Pillinger MH. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med 2011, 124:155-163. 10.1016/j.amjmed.2010.09.012, 21295195.